Form 4: Tenon Medical CIO Boosts Stake with PIPE Investment

Tenon Medical's Chief Innovation Officer, Wyatt D. Geist, increased his direct and indirect holdings through a private investment in public equity transaction.

Summary

• Wyatt D. Geist, Chief Innovation Officer and a 10% owner of Tenon Medical, Inc. (TNON), acquired additional shares and warrants.
• On November 14, 2025, Geist purchased 19,455 shares of common stock and warrants to purchase up to 19,455 shares of common stock.
• The purchase was part of an at-the-market private investment in public equity (PIPE) transaction, with the Securities Purchase Agreement entered into on November 10, 2025.
• The combined purchase price for each share of common stock and accompanying warrant was $1.285.
• The warrants have an exercise price of $1.16 and expire on November 14, 2028.
• Following this transaction, Geist directly beneficially owns 157,569 shares of common stock.
• Geist also indirectly beneficially owns 350,765 shares through SiVantage, Inc., a corporation in which he holds a 49.38% equity interest, which owns a total of 710,300 shares of Tenon Medical, Inc.

Sentiment

Score: 8

Explanation: The direct investment by a key executive, particularly the Chief Innovation Officer, is a strong positive signal, indicating internal confidence in the company's innovation and future growth.

Positives

• The Chief Innovation Officer's direct purchase of shares and warrants signals strong confidence in the company's future prospects and innovation strategy.
• Increased insider ownership aligns management's interests more closely with those of public shareholders.

Related Party Transactions

• Wyatt D. Geist, Chief Innovation Officer and a 10% owner, purchased 19,455 shares of common stock and 19,455 warrants from Tenon Medical, Inc. in a private investment transaction.
• The reporting person also has an indirect interest in 350,765 shares held by SiVantage, Inc., a corporation in which he holds a 49.38% equity interest, which owns a total of 710,300 shares of Tenon Medical, Inc.

Stakeholder Impact

• Shareholders may view the insider buying as a positive indicator of management's belief in the company's value and future prospects, potentially boosting investor confidence.
• The capital raise, in which the insider participated, provides additional funding to the company, which could support operations or strategic initiatives.

Key Dates

Recommendation

The Chief Innovation Officer's significant direct investment in the company's equity and warrants, through a PIPE transaction, signals strong conviction in Tenon Medical's innovation pipeline and long-term value. This insider buying activity, especially from a role critical to future product development, suggests a positive outlook that seasoned investors typically interpret as a 'buy' signal, aligning management's interests with shareholder returns.

Keywords

Tenon Medical, TNON, Insider Buying, Form 4, Private Investment in Public Equity, PIPE, Warrants, Common Stock, Wyatt Geist, Chief Innovation Officer, Ownership Change